These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21529245)

  • 1. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009: comments on the article by M Neovius et al.
    Ohlsson H; Merlo J
    Scand J Rheumatol; 2011 May; 40(3):243-4. PubMed ID: 21529245
    [No Abstract]   [Full Text] [Related]  

  • 2. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.
    Neovius M; Sundström A; Simard J; Wettermark B; Cars T; Feltelius N; Askling J; Klareskog L;
    Scand J Rheumatol; 2011 Jan; 40(1):8-15. PubMed ID: 20955087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deal watch : BMS acquires rights for IL-6 inhibitor.
    Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043020
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for rheumatoid arthritis.
    Drug Ther Bull; 2010 Jan; 48(1):9-12. PubMed ID: 20040568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S61-86. PubMed ID: 18097697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20 blockers eye crowded rheumatology market.
    Mack GS
    Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tumour necrosis factor therapy in the West Midlands.
    Bartram D; Sheeran T; Price T; Mulherin D
    Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
    Tsutani K; Igarashi A
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient access to rheumatoid arthritis treatments.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S33-4. PubMed ID: 18097698
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-inflammatory inflames Centocor's profits.
    Glaser V
    Nat Biotechnol; 1998 Oct; 16(10):900. PubMed ID: 9788334
    [No Abstract]   [Full Text] [Related]  

  • 18. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial.
    Pease C; Pope JE; Thorne C; Haraoui BP; Truong D; Bombardier C; Widdifield J; Psaradellis E; Sampalis JS; Bonner A
    J Rheumatol; 2010 Dec; 37(12):2469-74. PubMed ID: 20843910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide--not verified.
    April PA
    N Engl J Med; 2005 Oct; 353(14):1525-7; author reply 1525-7. PubMed ID: 16211707
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
    Mulherin D; Sheeran TP
    Arthritis Rheum; 2003 Mar; 48(3):868. PubMed ID: 12632461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.